Table 3 Univariate and multivariate analyses.
| Death/n | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | ||
| Age (y) | 0.41 | NS | |||
| ⩽70 | 27/41 (66%) | 1.0 | |||
| >70 | 18/29 (62%) | 1.3 (0.7–2.4) | |||
| Sex | 0.63 | NS | |||
| Female | 22/35 (63%) | 1.0 | |||
| Male | 23/35 (66%) | 1.2 (0.6–2.1) | |||
| UICC/TNM stage* | 0.59 | NS | |||
| pI† | 17/26 (65%) | 1.0 | |||
| pII† | 28/44 (64%) | 1.2 (0.6–2.2) | |||
| Tumour extent | 0.28 | NS | |||
| T1 | 9/16 (56%) | 1.0 | |||
| T2 | 32/46 (70%) | 1.5 (0.7–3.2) | |||
| T3 | 4/8 (50%) | 0.8 (0.2–2.6) | |||
| Lymph node disease | 0.23 | NS | |||
| N0 | 18/30 (60%) | 1.0 | |||
| N1 | 27/40 (68%) | 1.5 (0.8–2.7) | |||
| Tumour size (cm) | 0.47 | NS | |||
| 0–2 | 12/20 (60%) | 1.0 | |||
| >2 | 33/50 (66%) | 1.3 (0.7–2.5) | |||
| Tumour grade | |||||
| Well | 6/11 (55%) | 1.0 | 0.0001 | 1.0 | 0.0001 |
| Moderate | 16/33 (48%) | 1.4 (0.5–3.5) | 2.6 (0.9–7.3) | ||
| Poor | 23/26 (88%) | 5.0 (1.9–13.0) | 6.7 (2.4–18.5) | ||
| Perineural invasion | |||||
| No | 13/24 (54%) | 1.00 | 0.03 | 1.0 | 0.04 |
| Yes | 32/46 (70%) | 2.2 (1.1–4.2) | 2.1 (1.0–4.2) | ||
| Lymphovascular invasion | |||||
| No | 33/52 (63%) | 1.0 | NS | NS | |
| Yes | 12/18 (67%) | 1.5 (0.8–2.9) | |||
| K‐ras in margins | |||||
| No | 15/33 (45%) | 1.00 | 0.0013 | 1.0 | 0.004 |
| Yes | 30/37 (81%) | 2.8 (1.5–5.3) | 2.8 (1.4–5.5) | ||
| PanIN in margins‡ | |||||
| No | 1/3 | 1.0 | 0.67 | NS | |
| Yes | 11/27 | 0.72 (0.16–3.2) | |||
| K‐ras in tumour | |||||
| No | 11/13 (85%) | 1.0 | 0.15 | NS | |
| Yes | 34/57 (60%) | .60 (.30–1.2) | |||
*UICC/TNM 6th edition.
†pI and pII, pathological stage I and pathological stage II.
‡For patients with available pancreatic intraepithelial neoplasia data.
HR (95% CI), hazard ratio (95% confidence interval).